glp-1 obesity drugs updates today Antagonists Increase Plan Drug Spend - What's Next GLP-1 anti-obesity drugs lead to

Once determination has been granted by the TGA, the application for registration for a specific medicine (active ingredient) and priority indication may proceed

The number of overweight people has been increasing rapidly in recent years due to genetic, socio-economic, lifestyle, and cultural influences

The No-DAC variant is studied because it has a shorter duration of receptor engagement than long-acting formulations

The FDA has also raised concerns about dosing errors, contamination, impurities and inconsistent ingredients in compounded GLP-1 drugs

Cell Mol Life Sci 2005

A: Just like any part of a healthy lifestyle, you will only continue to see the benefits if you stay consistent with it